Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Supermax BhdSPMXF 46 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus rates SPMXF with a GF Score™ of 46/100 and a GF Value™ of $0.39. The stock has 6 warning signs investors should review. Among 692 Medical Devices & Instruments companies, Supermax Bhd ranks worse than 144508.53% on this metric.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Supermax Bhd was 190.60% per year. The lowest was -13.60% per year. And the median was 10.80% per year.
Supermax Bhd (OTCPK:SPMXF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Supermax Bhd 3-Year EBITDA Growth Rate Related Terms
SPMXF vs ISRG, BDX, MDLN: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Supermax Bhd's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supermax Bhd 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Supermax Bhd's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Supermax Bhd's 3-Year EBITDA Growth Rate falls into.
Supermax Bhd 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Supermax Bhd (SPMXF) has a 3-Year EBITDA Growth Rate of 0.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Supermax Bhd and its competitors. According to the industry distribution chart, Supermax Bhd ranks #999999 out of 692 companies in the Medical Devices & Instruments industry.
Is Supermax Bhd's 3-Year EBITDA Growth Rate too high?
Supermax Bhd's current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Supermax Bhd ranks #999999 out of 692 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Supermax Bhd has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Supermax Bhd's 3-Year EBITDA Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Supermax Bhd ranks #999999 out of 692 companies for 3-Year EBITDA Growth Rate. This places Supermax Bhd in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Supermax Bhd and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Supermax Bhd's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supermax Bhd stock overvalued right now?
Supermax Bhd (SPMXF) has a current 3-Year EBITDA Growth Rate of 0.00%. The stock's GF Value™ is $0.39, compared to a current price of $0.15 — trading 61.5% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 0.00%. Supermax Bhd's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Supermax Bhd (SPMXF), the current 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supermax Bhd (SPMXF) Overvalued in 2026?
Based on GuruFocus' analysis, Supermax Bhd stock appears to be undervalued.
The current stock price of $0.15 is trading 61.5% below its estimated GF Value™ of $0.39.
Key valuation signals for SPMXF:
3-Year EBITDA Growth Rate: 0.00%
GF Value™: $0.39 vs. price of $0.15 (61.5% below fair value)
No single metric tells the full story. See the SPMXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supermax Corp Bhd is an investment holding company. Along with its subsidiaries, the company operates as an international manufacturer, distributor, and marketer of high-quality medical gloves and contact lenses. It offers various types of latex gloves, which are exported to numerous countries. The company is organized into the following reportable operating segments: manufacturing of gloves, which generates the majority of revenue; investment holding; trading of gloves; and others. Geographically, it derives the majority of its revenue from Europe, with the remainder coming from Africa, Asia and Oceania, and North, Central, and South America.
46GF Score
Get the complete analysis for SPMXF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPMXF has been successfully added to your 
